Baudax Bio, a pharmaceutical company focused on innovative products for acute care, has announced additional positive results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. The analysis of electromyography (EMG) confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium. The trial was a randomized, double-blind, active-controlled study comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in 80 adult patients who had elective surgery utilizing total intravenous anesthesia. All patients across regimens met the primary efficacy criteria and recovery measures showed equivalent time for “full recovery” with tighter margins observed for BX1000 compared to rocuronium. Baudax Bio holds exclusive global rights to two novel NMBs: an intermediate duration blocking agent and an ultra-short duration blocking agent as well as a proprietary chemical reversal agent currently in nonclinical studies intended to support an investigational new drug submission by summer 2023.